Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab + nab-paclitaxel in previously treated urothelial carcinoma
ChiCTR2600123501Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Apr 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and paclitaxel in transitional cell carcinoma (TCC), sponsored by Shandong First Medical University. Primary endpoint: Progression-Free Survival (PFS). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxel
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2600123501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123501.